Guardant Health, Inc. GH

Full chart Compare
Set alert

Price alert · GH

All alert types
168.58 USD -6.42 (-3.67%)

At closeNov 4, 2026, 4:22 PM EST

168.58 0.00 0.00%

After hours · Nov 4, 4:22 PM ET

167.25 Day range 177.77
74.55 52-week range 191.05
YTD
+65.05%
1 year
+71.78%
Market cap
22.62B
Revenue (ttm)
1.18B
Profit margin
-38.33%
EPS (ttm)
-3.37
Shares out
134.20M
Forward P/E
-444.60
YTD return
+65.05%
1-year return
+71.78%
Volume
2.27M
Avg volume
1.89M
Open
176.49
Previous close
175.00
Day's range
167.25 – 177.77
52-week range
74.55 – 191.05
Beta
1.66
Analysts
Strong Buy
Price target
202.24 (+20.0%)
Earnings date
Nov 5, 2026

2Y +145.06 (+616.75%)

50100150200Jan 25Jun 25Nov 25Apr 26Aug 26168.58

Key statistics

Enterprise value
24.13B
PEG ratio
0.00
Price / sales
19.12
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
44.30%
Free cash flow
26.61M
Total cash
1.05B
Total debt
1.70B
Return on equity
0.00%
Short % of float
9.06%
50-day average
169.95
200-day average
131.11

Financials — quick view

All financials
GH Revenue — quarterly 334.98M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
GH Net income — quarterly -120.14M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
GH EPS — quarterly -0.90
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

GH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.75———
Jul 30, 2026Jun 30, 2026-0.76183-0.90-0.14-18.14%
May 7, 2026Mar 31, 2026-0.806-0.85-0.04-5.46%
Feb 19, 2026Dec 31, 2025-0.76677-1.00-0.23-30.42%
Oct 29, 2025Sep 30, 2025-0.78962-0.74+0.05+6.28%
Jul 30, 2025Jun 30, 2025-0.74051-0.80-0.06-8.03%

Upgrades / downgrades

GH analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026BTIGmainBuyBuy
Oct 23, 2026Roth Capitalinit—Buy
Oct 13, 2026Morgan StanleymainOverweightOverweight
Oct 7, 2026BarclaysmainOverweightOverweight
Oct 1, 2026GuggenheimmainBuyBuy
Sep 9, 2026UBSmainBuyBuy

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on GH — it syncs with the Stock Master app.

Insider holders

GH insider holders
InsiderRelationLatest transactionDateShares held
BELL MICHAEL BRIANChief Financial OfficerConversion of Exercise of derivative securityJun 30, 202651,816
CHUDOVA DARYAChief Technology OfficerSaleSep 14, 202670,635
EAGLE CRAIGOfficerConversion of Exercise of derivative securityMar 31, 202672,001
ELTOUKHY HELMY AChief Executive OfficerStock GiftAug 25, 20260
FREEMAN CHRISOfficerSaleAug 9, 202665,374
GADDE VIJAYA V.DirectorConversion of Exercise of derivative securityJun 16, 202628,517

Institution ownership

GH institution ownership
Holder% heldSharesValueReported
Blackrock Inc.5.68%7,622,9351.29BJun 29, 2026
Price (T.Rowe) Associates Inc4.85%6,514,9521.10BJun 29, 2026
Vanguard Capital Management LLC4.29%5,755,857970.32MJun 29, 2026
FMR, LLC4.09%5,488,272925.21MJun 29, 2026
Vanguard Portfolio Management LLC4.06%5,445,785918.05MJun 29, 2026
Invesco Ltd.3.30%4,429,755746.77MJun 29, 2026

Fund ownership

GH fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.98%3,999,645674.26MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.15%2,888,524486.95MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.1.33%1,778,489299.82MJun 29, 2026
Franklin Custodian Funds-FRANKLIN DYNATECH FUND1.30%1,750,000295.02MJun 29, 2026
Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund1.29%1,729,500291.56MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.24%1,665,905280.84MJun 29, 2026